Concepts (669)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medulloblastoma | 42 | 2022 | 702 | 4.140 |
Why?
|
| Cerebellar Neoplasms | 32 | 2022 | 589 | 3.340 |
Why?
|
| Cranial Irradiation | 29 | 2022 | 399 | 2.530 |
Why?
|
| Brain Neoplasms | 61 | 2022 | 8657 | 1.620 |
Why?
|
| Ependymoma | 13 | 2021 | 325 | 1.440 |
Why?
|
| Radiotherapy, Conformal | 11 | 2014 | 546 | 1.190 |
Why?
|
| Hodgkin Disease | 36 | 2012 | 1410 | 1.120 |
Why?
|
| Craniopharyngioma | 11 | 2021 | 279 | 1.060 |
Why?
|
| Photons | 9 | 2015 | 596 | 1.030 |
Why?
|
| Pituitary Neoplasms | 12 | 2021 | 1317 | 1.030 |
Why?
|
| Radiotherapy Dosage | 50 | 2022 | 2891 | 0.950 |
Why?
|
| Neoplasms, Second Primary | 18 | 2014 | 1024 | 0.930 |
Why?
|
| Astrocytoma | 13 | 2005 | 783 | 0.900 |
Why?
|
| Radiation Injuries | 18 | 2021 | 1167 | 0.880 |
Why?
|
| Child, Preschool | 145 | 2021 | 40440 | 0.790 |
Why?
|
| Rhabdomyosarcoma | 10 | 2014 | 381 | 0.750 |
Why?
|
| Child | 177 | 2022 | 75163 | 0.730 |
Why?
|
| Neoplasms, Radiation-Induced | 14 | 2013 | 550 | 0.730 |
Why?
|
| Germinoma | 8 | 2021 | 133 | 0.720 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 24 | 2004 | 1486 | 0.670 |
Why?
|
| Radiotherapy | 21 | 2015 | 1543 | 0.660 |
Why?
|
| Radiosurgery | 17 | 2005 | 1268 | 0.650 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 57 | 2021 | 11324 | 0.650 |
Why?
|
| Career Mobility | 3 | 2017 | 259 | 0.630 |
Why?
|
| Protons | 13 | 2022 | 1126 | 0.620 |
Why?
|
| Spinal Cord Neoplasms | 5 | 2021 | 269 | 0.600 |
Why?
|
| Central Nervous System Neoplasms | 7 | 2015 | 857 | 0.600 |
Why?
|
| Neuroectodermal Tumors, Primitive | 8 | 2015 | 138 | 0.600 |
Why?
|
| Adolescent | 159 | 2022 | 84401 | 0.570 |
Why?
|
| Radiotherapy, Intensity-Modulated | 7 | 2022 | 807 | 0.570 |
Why?
|
| Cranial Nerve Neoplasms | 5 | 2006 | 132 | 0.560 |
Why?
|
| Optic Nerve Glioma | 2 | 2006 | 31 | 0.520 |
Why?
|
| Combined Modality Therapy | 65 | 2022 | 8617 | 0.510 |
Why?
|
| Retinoblastoma | 8 | 2014 | 308 | 0.510 |
Why?
|
| Faculty, Medical | 6 | 2021 | 1167 | 0.490 |
Why?
|
| Infratentorial Neoplasms | 6 | 2017 | 97 | 0.460 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 6 | 2021 | 470 | 0.430 |
Why?
|
| Disease-Free Survival | 29 | 2022 | 6893 | 0.430 |
Why?
|
| Glioma | 11 | 2019 | 3318 | 0.430 |
Why?
|
| Radiotherapy, High-Energy | 6 | 2004 | 233 | 0.420 |
Why?
|
| Vincristine | 26 | 2015 | 1050 | 0.410 |
Why?
|
| Bone Marrow Transplantation | 18 | 2007 | 2768 | 0.410 |
Why?
|
| Supratentorial Neoplasms | 5 | 2015 | 162 | 0.390 |
Why?
|
| Methotrexate | 18 | 2012 | 1711 | 0.390 |
Why?
|
| Infant | 73 | 2021 | 34337 | 0.390 |
Why?
|
| Radiodermatitis | 2 | 2011 | 60 | 0.370 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 15 | 2022 | 1603 | 0.360 |
Why?
|
| Whole-Body Irradiation | 11 | 1998 | 450 | 0.350 |
Why?
|
| Bone Neoplasms | 12 | 2014 | 2512 | 0.340 |
Why?
|
| Male | 190 | 2021 | 347096 | 0.340 |
Why?
|
| Physicians, Women | 5 | 2008 | 473 | 0.340 |
Why?
|
| Optic Chiasm | 5 | 2014 | 87 | 0.330 |
Why?
|
| Neoplasm Staging | 25 | 2016 | 10950 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 24 | 2022 | 8918 | 0.320 |
Why?
|
| Humans | 256 | 2022 | 725187 | 0.320 |
Why?
|
| Female | 184 | 2022 | 375449 | 0.320 |
Why?
|
| Central Nervous System Cysts | 1 | 2007 | 58 | 0.310 |
Why?
|
| Lens, Crystalline | 2 | 2007 | 403 | 0.310 |
Why?
|
| Etoposide | 7 | 2015 | 637 | 0.300 |
Why?
|
| Orbital Neoplasms | 3 | 2005 | 217 | 0.290 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2012 | 360 | 0.290 |
Why?
|
| Leadership | 3 | 2018 | 1331 | 0.280 |
Why?
|
| Follow-Up Studies | 51 | 2018 | 38748 | 0.280 |
Why?
|
| Spinal Neoplasms | 4 | 2014 | 758 | 0.270 |
Why?
|
| Prejudice | 2 | 2007 | 560 | 0.270 |
Why?
|
| Parental Leave | 2 | 2021 | 75 | 0.260 |
Why?
|
| Prednisolone | 5 | 1994 | 337 | 0.260 |
Why?
|
| Brain Stem | 4 | 2022 | 832 | 0.260 |
Why?
|
| Survival Rate | 36 | 2015 | 12817 | 0.260 |
Why?
|
| Radiation Oncology | 2 | 2022 | 542 | 0.250 |
Why?
|
| Eye Neoplasms | 4 | 2003 | 304 | 0.250 |
Why?
|
| Pituitary Irradiation | 2 | 1994 | 17 | 0.250 |
Why?
|
| Preceptorship | 1 | 2004 | 59 | 0.250 |
Why?
|
| Treatment Outcome | 54 | 2021 | 61761 | 0.250 |
Why?
|
| Academic Medical Centers | 3 | 2017 | 2743 | 0.250 |
Why?
|
| Organs at Risk | 6 | 2022 | 349 | 0.240 |
Why?
|
| Radiation Injuries, Experimental | 4 | 1994 | 93 | 0.240 |
Why?
|
| Cysts | 1 | 2009 | 650 | 0.240 |
Why?
|
| Cyclophosphamide | 18 | 2015 | 2205 | 0.240 |
Why?
|
| Cisplatin | 8 | 2015 | 1633 | 0.240 |
Why?
|
| Etanidazole | 1 | 2003 | 26 | 0.240 |
Why?
|
| Radiotherapy, Adjuvant | 11 | 2021 | 1771 | 0.230 |
Why?
|
| Radiology Department, Hospital | 1 | 2006 | 407 | 0.220 |
Why?
|
| Relative Biological Effectiveness | 7 | 2021 | 330 | 0.220 |
Why?
|
| Stereotaxic Techniques | 5 | 1996 | 528 | 0.220 |
Why?
|
| Alopecia | 4 | 2014 | 377 | 0.210 |
Why?
|
| Thoracic Neoplasms | 3 | 2014 | 259 | 0.210 |
Why?
|
| Fund Raising | 1 | 2021 | 46 | 0.210 |
Why?
|
| Young Adult | 30 | 2022 | 55781 | 0.200 |
Why?
|
| Dose-Response Relationship, Radiation | 12 | 2008 | 879 | 0.200 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 3 | 2015 | 102 | 0.200 |
Why?
|
| Cancer Care Facilities | 1 | 2004 | 402 | 0.200 |
Why?
|
| Adult | 94 | 2022 | 211615 | 0.200 |
Why?
|
| Survival Analysis | 16 | 2016 | 10251 | 0.200 |
Why?
|
| Retrospective Studies | 46 | 2022 | 74206 | 0.200 |
Why?
|
| Brain Stem Neoplasms | 1 | 2003 | 198 | 0.200 |
Why?
|
| Cognition | 9 | 2021 | 6425 | 0.200 |
Why?
|
| Memory Disorders | 5 | 2018 | 1150 | 0.190 |
Why?
|
| Health Care Rationing | 1 | 2004 | 443 | 0.190 |
Why?
|
| Intelligence | 5 | 2018 | 912 | 0.190 |
Why?
|
| Prognosis | 29 | 2016 | 28737 | 0.180 |
Why?
|
| Organizational Policy | 2 | 2021 | 428 | 0.180 |
Why?
|
| Growth Disorders | 3 | 2022 | 637 | 0.180 |
Why?
|
| Diabetes Insipidus | 2 | 2016 | 153 | 0.180 |
Why?
|
| Linear Energy Transfer | 3 | 2017 | 166 | 0.180 |
Why?
|
| Mentors | 1 | 2004 | 613 | 0.180 |
Why?
|
| Doxorubicin | 19 | 2015 | 2226 | 0.180 |
Why?
|
| Optic Nerve Neoplasms | 1 | 1999 | 44 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 1752 | 0.170 |
Why?
|
| Sex Factors | 12 | 2021 | 10382 | 0.170 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2021 | 263 | 0.170 |
Why?
|
| Tectum Mesencephali | 1 | 1998 | 20 | 0.170 |
Why?
|
| Age Factors | 14 | 2018 | 18339 | 0.160 |
Why?
|
| SEER Program | 2 | 2013 | 1514 | 0.160 |
Why?
|
| Medulla Oblongata | 1 | 1999 | 243 | 0.160 |
Why?
|
| Spine | 2 | 2017 | 1108 | 0.160 |
Why?
|
| Confidence Intervals | 3 | 2017 | 2977 | 0.160 |
Why?
|
| Pituitary Gland | 2 | 2018 | 666 | 0.160 |
Why?
|
| Meningeal Neoplasms | 4 | 2015 | 1214 | 0.160 |
Why?
|
| Wechsler Scales | 1 | 2018 | 259 | 0.160 |
Why?
|
| Sarcoma | 6 | 2003 | 1889 | 0.150 |
Why?
|
| Abortion, Induced | 1 | 2022 | 411 | 0.150 |
Why?
|
| Hypophysectomy | 2 | 1994 | 114 | 0.150 |
Why?
|
| Neuropsychological Tests | 9 | 2018 | 6878 | 0.150 |
Why?
|
| Pediatrics | 3 | 2018 | 3441 | 0.150 |
Why?
|
| Drug Administration Schedule | 9 | 2013 | 4938 | 0.150 |
Why?
|
| Neoplasms, Multiple Primary | 5 | 2014 | 610 | 0.150 |
Why?
|
| Scattering, Radiation | 2 | 2017 | 500 | 0.150 |
Why?
|
| Spinal Cord | 3 | 2021 | 1812 | 0.140 |
Why?
|
| Mediastinal Neoplasms | 6 | 1997 | 427 | 0.140 |
Why?
|
| Gynecomastia | 1 | 2016 | 88 | 0.140 |
Why?
|
| Neurofibromatosis 1 | 3 | 2007 | 536 | 0.140 |
Why?
|
| Magnetic Resonance Spectroscopy | 5 | 2015 | 3693 | 0.140 |
Why?
|
| Survivors | 9 | 2020 | 2217 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 11 | 2013 | 3456 | 0.140 |
Why?
|
| Neurologic Examination | 3 | 1997 | 938 | 0.140 |
Why?
|
| Dactinomycin | 6 | 2006 | 321 | 0.130 |
Why?
|
| Neoplasms | 6 | 2021 | 20941 | 0.130 |
Why?
|
| Rhabdoid Tumor | 2 | 2017 | 203 | 0.130 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 1997 | 172 | 0.130 |
Why?
|
| Soft Tissue Neoplasms | 3 | 1997 | 1356 | 0.130 |
Why?
|
| Teratoma | 3 | 2017 | 390 | 0.130 |
Why?
|
| Transplantation Conditioning | 4 | 2007 | 1553 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 24 | 2016 | 34776 | 0.130 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2015 | 54 | 0.130 |
Why?
|
| Endocrine System | 1 | 2015 | 113 | 0.130 |
Why?
|
| Procarbazine | 9 | 2004 | 180 | 0.130 |
Why?
|
| Mediastinum | 3 | 2004 | 259 | 0.130 |
Why?
|
| Central Nervous System Diseases | 2 | 1997 | 523 | 0.130 |
Why?
|
| Prednisone | 13 | 2012 | 1549 | 0.120 |
Why?
|
| Time Factors | 18 | 2017 | 40186 | 0.120 |
Why?
|
| Leukemia, Lymphoid | 4 | 1988 | 316 | 0.120 |
Why?
|
| Neuroblastoma | 4 | 1997 | 1180 | 0.120 |
Why?
|
| Ploidies | 2 | 1994 | 281 | 0.120 |
Why?
|
| Radiology | 2 | 2007 | 2019 | 0.120 |
Why?
|
| Delayed Diagnosis | 2 | 2016 | 414 | 0.120 |
Why?
|
| Leukemia, Experimental | 1 | 1994 | 248 | 0.120 |
Why?
|
| Pituitary Gland, Posterior | 1 | 2013 | 43 | 0.120 |
Why?
|
| Transplantation Chimera | 3 | 2007 | 610 | 0.120 |
Why?
|
| Disease Progression | 11 | 2021 | 13157 | 0.120 |
Why?
|
| Neoplasm Seeding | 1 | 1993 | 87 | 0.120 |
Why?
|
| Oligodendroglioma | 2 | 1993 | 277 | 0.110 |
Why?
|
| Nasal Cavity | 1 | 2015 | 305 | 0.110 |
Why?
|
| Carboplatin | 2 | 2015 | 798 | 0.110 |
Why?
|
| Nose Neoplasms | 1 | 2015 | 244 | 0.110 |
Why?
|
| Monte Carlo Method | 5 | 2017 | 1297 | 0.110 |
Why?
|
| Retinal Neoplasms | 1 | 2014 | 140 | 0.110 |
Why?
|
| Treatment Failure | 8 | 2015 | 2614 | 0.110 |
Why?
|
| Hypothalamus | 1 | 2018 | 1070 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2003 | 1620 | 0.110 |
Why?
|
| Pelvic Neoplasms | 1 | 2014 | 255 | 0.110 |
Why?
|
| Pineal Gland | 1 | 2013 | 163 | 0.110 |
Why?
|
| Recurrence | 16 | 2014 | 8212 | 0.110 |
Why?
|
| Skull | 2 | 1994 | 808 | 0.110 |
Why?
|
| Cohort Studies | 15 | 2022 | 39918 | 0.100 |
Why?
|
| Neurosurgical Procedures | 1 | 2003 | 1995 | 0.100 |
Why?
|
| Moyamoya Disease | 2 | 2021 | 215 | 0.100 |
Why?
|
| Hippocampus | 3 | 2022 | 3604 | 0.100 |
Why?
|
| Brain | 15 | 2016 | 25764 | 0.100 |
Why?
|
| Quality of Life | 7 | 2020 | 12111 | 0.100 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2015 | 1656 | 0.100 |
Why?
|
| Incidence | 13 | 2017 | 20750 | 0.100 |
Why?
|
| Radiometry | 3 | 2018 | 800 | 0.100 |
Why?
|
| Brachytherapy | 3 | 1996 | 1246 | 0.100 |
Why?
|
| Dental Caries | 1 | 1995 | 434 | 0.100 |
Why?
|
| Mechlorethamine | 7 | 1993 | 135 | 0.100 |
Why?
|
| Postoperative Complications | 8 | 2003 | 15019 | 0.100 |
Why?
|
| Hypogonadism | 1 | 2016 | 772 | 0.100 |
Why?
|
| Hematologic Neoplasms | 4 | 2007 | 1725 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 19 | 2009 | 19908 | 0.100 |
Why?
|
| Schools, Medical | 1 | 2017 | 873 | 0.090 |
Why?
|
| Nervous System | 1 | 1994 | 560 | 0.090 |
Why?
|
| Endocrine System Diseases | 3 | 2018 | 248 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 6537 | 0.090 |
Why?
|
| Oral Health | 1 | 1995 | 452 | 0.090 |
Why?
|
| Periodicals as Topic | 3 | 2021 | 1415 | 0.090 |
Why?
|
| Remission Induction | 9 | 2005 | 2368 | 0.090 |
Why?
|
| Lung | 7 | 1995 | 9801 | 0.090 |
Why?
|
| Nervous System Neoplasms | 1 | 1990 | 91 | 0.090 |
Why?
|
| Behavior, Animal | 3 | 1994 | 1888 | 0.090 |
Why?
|
| Ifosfamide | 3 | 2006 | 226 | 0.090 |
Why?
|
| Prospective Studies | 17 | 2022 | 51869 | 0.090 |
Why?
|
| Cranial Nerve Injuries | 1 | 2009 | 25 | 0.090 |
Why?
|
| Cost Savings | 1 | 2015 | 913 | 0.090 |
Why?
|
| Emollients | 1 | 2009 | 33 | 0.090 |
Why?
|
| Vinblastine | 5 | 2012 | 505 | 0.090 |
Why?
|
| Executive Function | 1 | 2017 | 1305 | 0.090 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 1022 | 0.090 |
Why?
|
| Thorax | 2 | 2004 | 533 | 0.090 |
Why?
|
| Antineoplastic Agents | 6 | 2013 | 13576 | 0.080 |
Why?
|
| DNA, Neoplasm | 2 | 1997 | 1775 | 0.080 |
Why?
|
| Risk Assessment | 6 | 2017 | 23185 | 0.080 |
Why?
|
| Pelvic Bones | 2 | 2010 | 265 | 0.080 |
Why?
|
| United States | 13 | 2022 | 68403 | 0.080 |
Why?
|
| Analysis of Variance | 7 | 2018 | 6398 | 0.080 |
Why?
|
| Cognition Disorders | 5 | 2009 | 4011 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 2 | 2014 | 2671 | 0.080 |
Why?
|
| Radiation Dosage | 5 | 2007 | 1914 | 0.080 |
Why?
|
| Middle Aged | 45 | 2022 | 212292 | 0.080 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2003 | 1384 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 3628 | 0.080 |
Why?
|
| Hospitals | 1 | 2021 | 3730 | 0.080 |
Why?
|
| Pleural Effusion | 2 | 1989 | 329 | 0.070 |
Why?
|
| Cytogenetics | 1 | 2007 | 211 | 0.070 |
Why?
|
| Hypopituitarism | 1 | 2009 | 254 | 0.070 |
Why?
|
| Adenoma | 2 | 1996 | 2166 | 0.070 |
Why?
|
| Injections, Spinal | 6 | 2005 | 306 | 0.070 |
Why?
|
| Radiation-Protective Agents | 1 | 1986 | 88 | 0.070 |
Why?
|
| Chondrosarcoma | 1 | 2009 | 308 | 0.070 |
Why?
|
| Risk Factors | 22 | 2019 | 71009 | 0.070 |
Why?
|
| Brain Damage, Chronic | 3 | 1997 | 266 | 0.070 |
Why?
|
| Feasibility Studies | 5 | 2017 | 4940 | 0.070 |
Why?
|
| Women | 1 | 2008 | 227 | 0.070 |
Why?
|
| Health Services Accessibility | 2 | 2019 | 5059 | 0.070 |
Why?
|
| Proportional Hazards Models | 5 | 2015 | 12329 | 0.070 |
Why?
|
| Lymphocyte Transfusion | 2 | 2005 | 236 | 0.070 |
Why?
|
| Tumor Burden | 3 | 2021 | 1891 | 0.070 |
Why?
|
| Vomiting | 3 | 2021 | 613 | 0.070 |
Why?
|
| Graft vs Host Disease | 8 | 2005 | 2860 | 0.070 |
Why?
|
| Acetylcysteine | 1 | 1986 | 272 | 0.070 |
Why?
|
| Aspartic Acid | 2 | 2004 | 573 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 1999 | 3460 | 0.060 |
Why?
|
| alpha-Fetoproteins | 2 | 2013 | 230 | 0.060 |
Why?
|
| Hemorrhage | 1 | 1996 | 3354 | 0.060 |
Why?
|
| Necrosis | 1 | 2009 | 1626 | 0.060 |
Why?
|